Neuroscience CE Activities

Neuroscience blog

View Details

Improving the Management of Chronic Neurodegenerative Diseases with Interprofessional Collaboration & Care

Multiple sclerosis (MS) and Parkinson’s disease (PD) are 2 highly prevalent chronic progressive neurodegenerative disorders. Over time, the accumulation and subsequent worsening of the symptoms associated with these diseases can result in disability, impaired quality of life, loss of independence, and an increased burden on caregivers.  
View Details

New Treatments for SMA: Should We Offer Them to Adults?

Spinal muscular atrophy (SMA) is a genetic disorder and a devastating diagnosis for children and their families that can lead to death or a lifetime of severe disability and progressively limited mobility.

RMEI DECISION SUPPORT AIDS

View Details

The Evolving Role of Orexin-Based Therapy in Narcolepsy Type 1 Management

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.
View Details

Clearing the Path for the Accurate Diagnosis and Optimal Treatment of Bipolar Depression: A Clinical Convergence®

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.

LATEST NEUROSCIENCE ARTICLES

RSS Latest Neuroscience Articles
  • Fundamentals of Medical Ethics: Ethical Issues in Providing Care in Safety-Net Health Systems February 15, 2024
    Resource constraints in safety-net systems mean that outlays for care must be measured against opportunity costs. What ethical framework should guide resource allocation and management decisions?
    Dave A. Chokshi, Frederick P. Cerise
  • Silencing Immune Dialogue in Multiple Sclerosis February 15, 2024
    Multiple sclerosis has two principal forms. Relapsing multiple sclerosis is characterized by recurrent attacks, initially with remissions but over time leading to lasting disability. In progressive multiple sclerosis, continuous worsening that leads to a wheelchair- or bed-bound state is typical. Progressive multiple sclerosis usually develops after a period of relapsing...
    Stephen L. Hauser
  • Inhibition of CD40L with Frexalimab in Multiple Sclerosis February 15, 2024
    In a phase 2 trial involving participants with multiple sclerosis, the CD40L inhibitor frexalimab reduced the accumulation of new lesions on MRI at week 12 of treatment.
    Patrick Vermersch, Cristina Granziera, Yang Mao-Draayer, Gary Cutter, Oleksandr Kalbus, Ivan Staikov, Michal Dufek, Stephane Saubadu, Raphael Bejuit, Philippe Truffinet, Biljana Djukic, Erik Wallstroem, Gavin Giovannoni, the Frexalimab Phase 2 Trial Group

RMEI LIGHTNING TALKS

View Details

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.
View Details

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.